Orbit Discovery

Orbit Discovery is a private, platform-focused biotech service company specializing in peptide discovery for partners in the pharmaceutical industry. Its core technology combines bead-based peptide display with microfluidic sorting and flow cytometry, enabling the screening of vast libraries (linear and macrocyclic) for both affinity and direct functional activity. The company operates as a service provider, collaborating with biotech and pharma partners to identify peptide hits for a wide range of therapeutic modalities, with a strong focus on targeted radionuclide therapy and complex functional screens. Orbit appears to be in an early-revenue stage, leveraging its platform through collaborative partnerships rather than developing its own proprietary drug pipeline.

Proprietary bead-based peptide display system integrated with microfluidics and flow cytometry for high-throughput screening of linear and macrocyclic peptide libraries. Capable of both affinity-based screening and direct functional screening using reporter cell lines.

Orbit Discovery competes with other peptide discovery platform companies (e.g., those using phage, mRNA, or yeast display) and CROs offering early-stage drug discovery services. Its differentiation lies in the combination of bead-based display, microfluidic sorting, and direct functional screening capabilities, particularly for complex targets like GPCRs.